Leading Through a Crisis as a First-time Group CEO

Once a major importer of Russian gas, Uniper faced financial turmoil in 2022, culminating in an adjusted EBIT loss of €10.9 billion—due in large part to the non-delivery of gas from Russia—and stabilisation measures implemented by the German Government. Michael Lewis, who took on the Group CEO role in 2023, talks to Criticaleye about a bold strategy to rebuild the company as a sustainable energy provider

For leaders undertaking complex transformation programmes, Criticaleye's highly bespoke leadership development offers CEOs and senior executives the chance to ask questions and compare approaches with peers from different organisations, sectors and regions. Get in touch with our team here to discuss how to join our global Community of senior leaders. 
 




Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.

Click here to download this insight
Accelerating Your Path to CPO...

Criticaleye has over 21 years of experience transforming global leaders including aspiring Chief People Officers (CPO).

Click here to download this insight
The Board's Role in M&A

In this exclusive interview with Criticaleye, Oliver Tant, Non-executive Director at UK household name B&M Retail and former CFO of FTSE 100 stalwart Imperial Brands, highlights the vital role of the Board in provid...

Click here to download this insight
CPO Research Results 2025

This research, conducted at our CPO Retreat, provides a fascinating insight into the challenges and priorities for Chief People Officers (CPOs) this year. Key findings from Criticaleye's CPO Research: Tec...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 394




Legal & General Investment Management Lightsource bp Google Amazon UK Hitachi Solutions Accenture LDC NATS Eightfold AI Royal London Group Workday Activision Blizzard Palo Alto Networks FTSE Women Leaders Review IBM Consulting AlixPartners Salesforce Concentrix E.ON UK Experian London Stock Exchange Group Rolls-Royce Drax Group plc GlaxoSmithKline plc